You are here:Home-Chemical Inhibitors & Agonists-Proteasome/Ubiquitin-Deubiquitinase (DUB)-I-138
I-138

Chemical Structure : I-138

CAS No.: 2098211-50-6

I-138 (USP1 inhibitor I-138)

Catalog No.: PC-49689Not For Human Use, Lab Use Only.

I-138 (I 138) is a potent, specific small molecule USP1-UAF1 inhibitor with IC50 of 4.1 nM, binds to USP1-UAF1 at an allosteric pocket synergistically with ubiquitin.

Packing Price Stock Quantity
5 mg $258 In stock
10 mg $398 In stock
25 mg $588 In stock
50 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

I-138 (I 138) is a potent, specific small molecule USP1-UAF1 inhibitor with IC50 of 4.1 nM, binds to USP1-UAF1 at an allosteric pocket synergistically with ubiquitin.
I-138 displays exquisite selectivity (>2,000-fold) across a panel of 45 deubiquitinating enzymes (Ubiquigent DUBprofiler) at 10 uM, including the closely related USP12-UAF1 and USP46-UAF1 complexes.
I-138 treatment (500 nM, 4 hours) increased PCNA and FANCD2 monoubiquitination in HAP-1 USP1 WT but not knockout cells, induced the monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells, also ablated USP1 autocleavage in cells.
I-138 (0-10 uM) selectively caused loss of viability (IC50=50 nM) and replication stress in BRCA1/2 mutant cells (MDA-MB-436 cell), but not the WT breast cancer cell line HCC1954.
I-138 displayed improved potency and physiochemical properties suitable for in vivo studies compared with ML323.
I-138 demonstarted strongly synergistic effect with PARP inhibitor Olaparib in a BRCA1/2-dependent manner in vitro, and in mice bearing MDA-MB-436 tumors.

Physicochemical Properties

M.Wt 492.51
Formula C26H23F3N6O
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

2-(2-isopropylphenyl)-9-(4-(1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-7,9-dihydro-8H-purin-8-one

References

1. Patent WO/2017/087837.

2. Antoine Simoneau, et al. Mol Cancer Ther. 2023 Feb 1;22(2):215-226.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: